Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry

[1] van Leeuwen FE(1994)Risk of endometrial cancer after tamoxifen treatment of breast cancer Lancet 343 448-452

[2] Benraadt J(1995)Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group J Natl Cancer Inst 87 645-651

[3] Goebergh JW(1998)Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1371-1388

[4] Kiemeney LA(2002)First results from the International Breast Cancer Intervention Study: a randomized prevention trial Lancet 360 817-824

[5] Gimbrere CH(1991)Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen J Natl Cancer Inst 83 1477-1482

[6] Otter R(1993)Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites J Natl Cancer Inst 85 806-812

[7] Rutqvist LE(2000)Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours Br J Cancer 82 1629-1635

[8] Johansson H(1997)Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes Biochem Pharmacol 52 171-178

[9] Signomklao T(2004)Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for prominent roles for CYP3A and CYP2D6 J Pharmacol Exp Ther 310 1062-1075

[10] Johansson U(2005)Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen Cancer Chemother Pharmacol 55 471-478

[1] van Leeuwen FE(1994)Risk of endometrial cancer after tamoxifen treatment of breast cancer Lancet 343 448-452

[2] Benraadt J(1995)Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group J Natl Cancer Inst 87 645-651

[3] Goebergh JW(1998)Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1371-1388

[4] Kiemeney LA(2002)First results from the International Breast Cancer Intervention Study: a randomized prevention trial Lancet 360 817-824

[5] Gimbrere CH(1991)Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen J Natl Cancer Inst 83 1477-1482

[6] Otter R(1993)Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites J Natl Cancer Inst 85 806-812

[7] Rutqvist LE(2000)Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours Br J Cancer 82 1629-1635

[8] Johansson H(1997)Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes Biochem Pharmacol 52 171-178

[9] Signomklao T(2004)Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for prominent roles for CYP3A and CYP2D6 J Pharmacol Exp Ther 310 1062-1075

[10] Johansson U(2005)Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen Cancer Chemother Pharmacol 55 471-478